
Patenting and Intellectual Property Considerations for HIV Prevention & MPTs
This webinar in the “Let’s Talk MPTs” discussion series was held in partnership between the Initiative for MPTs (IMPT) and Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX). The webinar provides a valuable opportunity to hear from MPT and HIV prevention product developers and other experts on the following topics related to intellectual property and patenting considerations necessary for bringing MPTs and HIV prevention products to market:
- Patent protection
- Accessing APIs
- Freedom to operate
- Royalties Tech transfer
Featured speakers included Ian McGowan from Orion Biotechnology, Nataliya Omelchuk from Medicines Patent Pool, and Akash Bakshi from YourChoice Therapeutics.
View Webinar Recording
Download Presentation
Download Suggested Readings
June 2022
Click for full info +Full Info:
Resource Type:
Citation:
This webinar in the “Let’s Talk MPTs” discussion series was held in partnership between the Initiative for MPTs (IMPT) and Microbicide R&D to Advance HIV Prevention Technologies through Responsive Innovation and eXcellence (MATRIX). The webinar provides a valuable opportunity to hear from MPT and HIV prevention product developers and other experts on the following topics related to intellectual property and patenting considerations necessary for bringing MPTs and HIV prevention products to market:
- Patent protection
- Accessing APIs
- Freedom to operate
- Royalties Tech transfer
Featured speakers included Ian McGowan from Orion Biotechnology, Nataliya Omelchuk from Medicines Patent Pool, and Akash Bakshi from YourChoice Therapeutics.
Authors: The IMPT, Ian McGowan, Nataliya Omelchuk, Akash Bakshi
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- MPTs
Topic(s):
- MPTs
- Development
Region(s)
- Global
Additional Keywords:
Patenting, Intellectual Property